Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes

References

• Bindschedler M, Degen P, Flesch G, de Gasparo M, Preiswerk G. 1997. Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide. European Journal of Clinical Pharmacology 52:371–378.
   PubMed Web of Science ®Google Scholar
• Black HR, Graff A, Shute D, Stoltz R, Ruff D, Levine J, Shi Y, Mallows S. 1997. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. Journal of Human Hypertension 11:483–489.
   PubMed Web of Science ®Google Scholar
• Bort R, Mace K, Boobis A, Gomez-Lechon MJ, Pfeifer A, Castell J. 1999. Hepatic metabolism of diclofenac: Role of human GYP in the minor oxidative pathways. Biochemical Pharmacology 58:787–796.
   PubMed Web of Science ®Google Scholar
• Bourrie M, Meunier V, Berger Y, Fabre G. 1996. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics 277:321–332.
   PubMed Web of Science ®Google Scholar
• Brookman LJ, Rolan PE, Benjamin IS, Palmer KR, Wyld PJ, Lloyd P, Flesch G, Waldmeier F, Sioufi A, Mullins F. 1997. Pharmacokinetics of valsartan in patients with liver disease. Clinical Pharmacology and Therapeutics 62:272–278.
   PubMed Web of Science ®Google Scholar
• Clarke SE, Ayrton AD, Chenery RJ. 1994. Characterization of the inhibition of P4501A2 by furafylline. Xenobiotica 24:517–526.
   PubMed Web of Science ®Google Scholar
• Colussi DM, Parisot C, Rossolino ML, Brunner LA, Lefevre GY. 1997. Protein binding in plasma of valsartan, a new angiotensin II receptor antagonist. Journal of Clinical Pharmacology 37:214–221.
   PubMed Web of Science ®Google Scholar
• Corea L, Cardoni O, Fogari R, Innocenti P, Porcellati C, Provvidenza M, Meilenbrock S, Sullivan J, Bodin F. 1996. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: A comparative study of the efficacy and safety against amlodipine. Clinical Pharmacology and Therapeutics 60:341–346.
   PubMed Web of Science ®Google Scholar
• Criscione L, Bradley WA, Bühlmayer P, Whitebread S, Glazer R, Lloyd P, Muller P, de Gasparo M. 1995. Valsartan: Preclinical and clinical profile of an antihypertensive angiotensin-II antagonist. Cardiovascular Drug Review 13:230–250.
   Google Scholar
• Criscione L, de Gasparo M, Bühlmayer P, Whitebread S, Ramjoue HP, Wood J. 1993. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. British Journal of Pharmacology 110:761–771.
   PubMed Web of Science ®Google Scholar
• Czendlik CH, Sioufi A, Preiswerk G, Howald H. 1997. Pharmacokinetic and pharmacodynamic interaction of single doses of valsartan and atenolol. European Journal of Clinical Pharmacology 52:451–459.
   PubMed Web of Science ®Google Scholar
• Fischer V, Johanson L, Heitz F, Tullman R, Graham E, Baldeck JP, Robinson WT. 1999. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: Effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metabolism and Disposition 27:410–416.
   PubMed Web of Science ®Google Scholar
• Flesch G, Muller P, Lloyd P. 1997. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. European Journal of Clinical Pharmacology 52:115–120.
   PubMed Web of Science ®Google Scholar
• Flesch G, Muller PH, Degen P, Lloyd P, Dieterle W. 1993. Repeated dose pharmacokinetics of valsartan, a new angiotensin-II antagonist, in healthy subjects. European Journal of Drug Metabolism and Pharmacokinetics 18:abst 256.
   Google Scholar
• Franklin MR. 1977. Inhibition of mixed-function oxidation by substrates forming reduced cytochrome P-450 metabolic-intermediate complex. Pharmacology and Therapeutics A 2:227–245.
   Google Scholar
• Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM, Ghanayem BI. 1994. Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans. Biochemistry 33: 1743–1752.
   PubMed Web of Science ®Google Scholar
• Gonzalez FJ. 1992. Human cytochromes P450: Problems and prospects. Trends in Pharmacological Science 13:346–352.
   PubMed Web of Science ®Google Scholar
• Guengerich FP. 1994. Catalytic selectivity of human cytochrome P450 enzymes: Relevance to drug metabolism and toxicity. Toxicology Letters 70:133–138.
   PubMed Web of Science ®Google Scholar
• Holwerda NJ, Fogari R, Angeli P, Porcellati C, Hereng C, Oddou-Stock P, Heath R, Bodin F. 1996. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. Journal of Hypertension 14:1147–1151.
   PubMed Web of Science ®Google Scholar
• Horai Y, Ishizaki T. 1988. Pharmacogenetics and its clinical implications. Part II. Oxidation polymorphism. Rational Drug Therapy 22:1–8.
   PubMedGoogle Scholar
• Leemann T, Transon C, Dayer P. 1993. Cytochrome P450TB (CYP2C): A major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver. Life Sciences 52:29–34.
   PubMed Web of Science ®Google Scholar
• Markham A, Goa KL. 1997. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs 54:299–311.
   Google Scholar
• Muller P, Flesch G, de Gasparo M, Gasparini M, Howald H. 1997. Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects. European Journal of Clinical Pharmacology 52:115–120.
   PubMedGoogle Scholar
• Muller P, Flesch G, de Gasparo M, Turn M, Preiswerk G, Howald H. 1993. Single and multiple dose phase I trials with the angiotensin II antagonist valsartan. Journal of Hypertension 12:S459.
   Google Scholar
• Newton DJ, Wang RW, Lu AY. 1995. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition 23:154–158.
   Google Scholar
• Prasad P, Mangat S, Yeh CM, Glazer R. 1999. Lack of interaction between valsartan and digoxin in healthy subjects. American Journal of Hypertension 12(4 Part 2): 124A, abst D053.
   Google Scholar
• Schenkman JB, Wilson BJ, Cinti DL. 1972. Dimethylaminoethyl 2,2-diphenylvalerate HC1 (SKF 525-A)-in vivo and in vitro effects of metabolism by rat liver microsomes-formation of an oxygenated complex. Biochemical Pharmacology 21:2373–2383.
   Google Scholar
• Schmidt EK, Antonin KH, Flesch G, Racine-Poon A. 1998. An interaction study with cimetidine and the new angiotensin II antagonist valsartan. European Journal of Clinical Pharmacology 53:451–458.
   PubMed Web of Science ®Google Scholar
• Sesardic D, Boobis AR, Murray BP, Murray S, Segura J, de la Torre R, Davies DS. 1990. Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. British Journal of Clinical Pharmacology 29:651–663.
   PubMed Web of Science ®Google Scholar
• Taavitsainen P, Kiukaanniemi K, Pelkonen O. 2000. In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists. European Journal of Clinical Pharmacology 56:135–140.
   PubMed Web of Science ®Google Scholar
• Transon C, Lecoeur S, Leemann T, Beaune P, Dayer P. 1996. Interindividual variability in catalytic activity and immunoreactivity of three major human liver cytochrome P450 isozymes. European Journal of Clinical Pharmacology 51:79–85.
   PubMed Web of Science ®Google Scholar
• Waldmeier F, Flesch G, Muller P, Winkler T, Kriemler HP, Buhlmayer P, de Gasparo M. 1997. Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica 27:59–71.
   Google Scholar
• Wrighton SA, Stevens JC, Becker GW, VandenBranden M. 1993. Isolation and characterization of human liver cytochrome P450 2C19: Correlation between 2C19 and 5-mephenytoin 4'-hydroxylation. Archives of Biochemistry and Biophysics 306:240–245.
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Inoue K, Chiba K, Ozawa N, Kawai T, Suzuki Y, Goldstein JA, Guengerich FP, Shimada T. 1998. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Biochemical Pharmacology 56:243–251.
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Shimada T. 1998. Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin. Drug Metabolism and Disposition 26:1053–1057.
   PubMed Web of Science ®Google Scholar